EE200200045A - Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid - Google Patents
Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendidInfo
- Publication number
- EE200200045A EE200200045A EEP200200045A EEP200200045A EE200200045A EE 200200045 A EE200200045 A EE 200200045A EE P200200045 A EEP200200045 A EE P200200045A EE P200200045 A EEP200200045 A EE P200200045A EE 200200045 A EE200200045 A EE 200200045A
- Authority
- EE
- Estonia
- Prior art keywords
- compounds
- intermediates
- pharmaceutical composition
- factor
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000012450 pharmaceutical intermediate Substances 0.000 title 1
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 108010029144 Factor IIa Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Dental Preparations (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36319699A | 1999-07-28 | 1999-07-28 | |
| PCT/IB2000/001156 WO2001007436A2 (en) | 1999-07-28 | 2000-07-26 | Substituted oxoazaheterocyclyl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200200045A true EE200200045A (et) | 2003-06-16 |
Family
ID=23429232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200045A EE200200045A (et) | 1999-07-28 | 2000-07-26 | Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1208097B1 (et) |
| JP (1) | JP4829449B2 (et) |
| KR (1) | KR20020087041A (et) |
| CN (1) | CN1420882A (et) |
| AT (1) | ATE423113T1 (et) |
| AU (1) | AU773227B2 (et) |
| BG (1) | BG106340A (et) |
| BR (1) | BR0013179A (et) |
| CA (1) | CA2382755A1 (et) |
| CR (1) | CR6563A (et) |
| CZ (1) | CZ2002323A3 (et) |
| DE (1) | DE60041584D1 (et) |
| EE (1) | EE200200045A (et) |
| HK (1) | HK1054227A1 (et) |
| HR (1) | HRP20020076A2 (et) |
| HU (1) | HUP0203375A3 (et) |
| IL (2) | IL147495A0 (et) |
| MX (1) | MXPA02000888A (et) |
| NO (1) | NO20020214L (et) |
| PL (1) | PL354998A1 (et) |
| RU (1) | RU2002105011A (et) |
| SK (1) | SK1182002A3 (et) |
| TR (1) | TR200200225T2 (et) |
| WO (1) | WO2001007436A2 (et) |
| ZA (1) | ZA200200543B (et) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020082896A (ko) | 2000-03-21 | 2002-10-31 | 스미스클라인 비참 코포레이션 | 프로테아제 억제제 |
| US20040072860A1 (en) * | 2000-09-29 | 2004-04-15 | Bing-Yan Zhu | Piperazin-2-one amides as inhibitors of factor xa |
| KR20030079979A (ko) * | 2001-02-02 | 2003-10-10 | 브리스톨-마이어스스퀴브컴파니 | 치환된 아자인돌옥소아세틱 피페라진 유도체의 조성물 및항바이러스 활성 |
| GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0114004D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0114005D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| NZ530202A (en) | 2001-07-02 | 2005-06-24 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| AU2007229363B2 (en) * | 2001-08-24 | 2009-06-04 | University Of South Florida | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and the Methods of Treatment |
| ES2335092T3 (es) * | 2001-08-24 | 2010-03-22 | Yale University | Compuestos de piperazinona como agentes antitumorales y anticancer. |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| US7087604B2 (en) | 2002-03-08 | 2006-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| AU2003231359B2 (en) | 2002-04-16 | 2009-04-30 | Teijin Limited | Piperidine derivatives having CCR3 antagonism |
| KR20040104596A (ko) | 2002-04-25 | 2004-12-10 | 데이진 가부시키가이샤 | Ｃｃｒ３ 길항 작용을 갖는 ４,４-２치환 피페리딘 유도체 |
| TW200409637A (en) | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
| WO2004032930A1 (ja) * | 2002-10-11 | 2004-04-22 | Kowa Co., Ltd. | 癌の処置方法 |
| US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
| AU2003298034B2 (en) * | 2002-12-06 | 2011-04-21 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
| US8729107B2 (en) | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
| US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| AU2004218115A1 (en) | 2003-03-07 | 2004-09-16 | Astellas Pharma Inc. | Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| AU2004261582C1 (en) | 2003-07-22 | 2010-01-07 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| WO2006019497A2 (en) | 2004-06-17 | 2006-02-23 | Neurocrine Biosciences, Inc. | Sleep-inducing compounds and methods related thereto |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| KR101063663B1 (ko) | 2005-02-17 | 2011-09-07 | 아스텔라스세이야쿠 가부시키가이샤 | 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체 |
| US20080200431A1 (en) * | 2005-07-08 | 2008-08-21 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
| WO2007008144A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| ES2397418T3 (es) | 2005-07-21 | 2013-03-06 | Astrazeneca Ab | Derivados de piperidina |
| US8143285B2 (en) * | 2005-09-06 | 2012-03-27 | Shionogi & Co., Ltd. | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity |
| EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
| ES2625378T3 (es) | 2005-09-27 | 2017-07-19 | Shionogi & Co., Ltd. | Derivado de sulfonamida que tiene actividad antagonista del receptor de PGD2 |
| CA2634743C (en) | 2005-12-23 | 2014-07-29 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EP2007377A4 (en) | 2006-04-06 | 2011-08-17 | Glaxo Group Ltd | ANTIBACTERIAL ACTIVE SUBSTANCES |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| WO2007140263A2 (en) * | 2006-05-26 | 2007-12-06 | University Of Louisville Research Foundation, Inc. | Macrophage migration inhibitory factor antagonists and methods of using same |
| EP1882688A1 (en) * | 2006-07-25 | 2008-01-30 | EPFL Ecole Polytechnique Fédérale de Lausanne | Labelling of fusion proteins with synthetic probes |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| PL2468724T3 (pl) | 2006-12-21 | 2016-05-31 | Zealand Pharma As | Synteza związków pirolidynowych |
| CN101679347B (zh) * | 2007-03-20 | 2014-10-22 | 柯瑞斯公司 | 作为hsp90抑制剂的稠和的氨基吡啶 |
| WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| CN104739829B (zh) | 2008-10-28 | 2018-11-06 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| WO2011038234A2 (en) | 2009-09-24 | 2011-03-31 | University Of Louisville Research Foundation, Inc. | Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions |
| WO2011146824A1 (en) | 2010-05-20 | 2011-11-24 | University Of Louisville Research Foundation, Inc. | Methods and compositions for modulating ocular damage |
| KR101251282B1 (ko) | 2010-10-18 | 2013-04-10 | 서울대학교산학협력단 | 프로스타글란딘 합성을 억제하는 설폰아미드 유도체 및 이를 포함하는 약학적 조성물 |
| CN103261205B (zh) * | 2010-11-12 | 2015-08-19 | 姚雪彪 | 动点马达蛋白cenp-e小分子抑制剂syntelin及其应用 |
| JP5951625B2 (ja) | 2010-11-24 | 2016-07-13 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ | 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト |
| PL395470A1 (pl) | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
| US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
| WO2014151936A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles, their preparation and use |
| ES2705247T3 (es) | 2013-03-14 | 2019-03-22 | Univ Columbia | 4-fenilpiperidinas, su preparación y uso |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| EP2968303B1 (en) | 2013-03-14 | 2018-07-04 | The Trustees of Columbia University in the City of New York | Octahydrocyclopentapyrroles, their preparation and use |
| AU2015253232B2 (en) | 2014-04-30 | 2020-10-01 | The Trustees Of Columbia University In The City Of New York | Substituted 4-phenylpiperidines, their preparation and use |
| US10414733B2 (en) | 2014-07-31 | 2019-09-17 | Basf Se | Process for preparing pyrazoles |
| CN104610257B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺结构的FXa抑制剂、制备方法及其用途 |
| CN104610258B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途 |
| CN104557928B (zh) * | 2015-02-14 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途 |
| CN104672236B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途 |
| CN104557929B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
| CN104672235B (zh) * | 2015-02-14 | 2016-02-17 | 佛山市赛维斯医药科技有限公司 | 一类含双酰胺基和烷氧苯基结构的FXa抑制剂及其用途 |
| CN104557930B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂及其用途 |
| CN104557927B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途 |
| CN104592227B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途 |
| CN104650081B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 凝血因子Xa抑制剂、制备方法及其用途 |
| CN104610260B (zh) * | 2015-02-14 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途 |
| CN104610259B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途 |
| CN104650082B (zh) * | 2015-02-14 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类凝血因子Xa抑制剂、制备方法及其用途 |
| WO2016180833A1 (en) | 2015-05-11 | 2016-11-17 | Basf Se | Process for preparing 4-amino-pyridazines |
| KR20180022792A (ko) | 2015-06-12 | 2018-03-06 | 엑소반트 사이언시즈 게엠베하 | 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체 |
| CA2988572A1 (en) | 2015-06-26 | 2016-12-29 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| EP3366679B1 (en) * | 2015-10-20 | 2021-03-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
| JP7145875B2 (ja) | 2017-04-18 | 2022-10-03 | 武田薬品工業株式会社 | アセチルコリン受容体のモジュレーターとして有用な複素環化合物 |
| EP3618847B1 (en) | 2017-05-05 | 2021-04-07 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
| CN110054619A (zh) * | 2018-01-18 | 2019-07-26 | 西北农林科技大学 | 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂 |
| MX2020010657A (es) | 2018-04-10 | 2020-10-28 | Bayer Ag | Derivados de oxadiazolina. |
| CN109991355B (zh) * | 2019-04-12 | 2021-05-11 | 中国烟草总公司郑州烟草研究院 | 一种鉴定动物体内nab代谢产物的方法和评价nab在动物体内暴露风险的方法 |
| WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI953916A0 (fi) * | 1993-02-22 | 1995-08-21 | Merck & Co Inc | Fibrinogeenireseptoriantagonisteja |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
| UA56197C2 (uk) * | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
| CA2285335A1 (en) * | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| WO1999033805A1 (en) * | 1997-12-26 | 1999-07-08 | Mochida Pharmaceutical Co., Ltd. | Aromatic compounds having cyclic amino or salts thereof |
| BR9907300A (pt) * | 1998-01-27 | 2000-10-24 | Aventis Pharm Prod Inc | Inibidores do fator xa oxoaza-heterociclila substituìdos |
| CA2317017A1 (en) * | 1998-02-05 | 1999-08-12 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, their production and use |
| JP2000204081A (ja) * | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
| JP2003529531A (ja) * | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルＸａ因子阻害剤 |
-
2000
- 2000-07-26 SK SK118-2002A patent/SK1182002A3/sk unknown
- 2000-07-26 DE DE60041584T patent/DE60041584D1/de not_active Expired - Lifetime
- 2000-07-26 HU HU0203375A patent/HUP0203375A3/hu unknown
- 2000-07-26 AU AU64628/00A patent/AU773227B2/en not_active Ceased
- 2000-07-26 CA CA002382755A patent/CA2382755A1/en not_active Abandoned
- 2000-07-26 RU RU2002105011/04A patent/RU2002105011A/ru unknown
- 2000-07-26 EP EP00951781A patent/EP1208097B1/en not_active Expired - Lifetime
- 2000-07-26 EE EEP200200045A patent/EE200200045A/et unknown
- 2000-07-26 CZ CZ2002323A patent/CZ2002323A3/cs unknown
- 2000-07-26 JP JP2001512520A patent/JP4829449B2/ja not_active Expired - Fee Related
- 2000-07-26 TR TR2002/00225T patent/TR200200225T2/xx unknown
- 2000-07-26 KR KR1020027001192A patent/KR20020087041A/ko not_active Withdrawn
- 2000-07-26 HK HK03106404.4A patent/HK1054227A1/zh unknown
- 2000-07-26 WO PCT/IB2000/001156 patent/WO2001007436A2/en not_active Ceased
- 2000-07-26 HR HR20020076A patent/HRP20020076A2/hr not_active Application Discontinuation
- 2000-07-26 BR BR0013179-2A patent/BR0013179A/pt not_active IP Right Cessation
- 2000-07-26 IL IL14749500A patent/IL147495A0/xx active IP Right Grant
- 2000-07-26 AT AT00951781T patent/ATE423113T1/de not_active IP Right Cessation
- 2000-07-26 PL PL00354998A patent/PL354998A1/xx not_active Application Discontinuation
- 2000-07-26 CN CN00810877A patent/CN1420882A/zh active Pending
- 2000-07-26 MX MXPA02000888A patent/MXPA02000888A/es active IP Right Grant
-
2002
- 2002-01-06 IL IL147495A patent/IL147495A/en not_active IP Right Cessation
- 2002-01-15 NO NO20020214A patent/NO20020214L/no not_active Application Discontinuation
- 2002-01-22 ZA ZA200200543A patent/ZA200200543B/en unknown
- 2002-01-22 BG BG106340A patent/BG106340A/xx unknown
- 2002-01-25 CR CR6563A patent/CR6563A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1208097B1 (en) | 2009-02-18 |
| WO2001007436A2 (en) | 2001-02-01 |
| NO20020214D0 (no) | 2002-01-15 |
| BG106340A (en) | 2002-10-31 |
| AU773227B2 (en) | 2004-05-20 |
| PL354998A1 (en) | 2004-03-22 |
| HRP20020076A2 (en) | 2003-12-31 |
| EP1208097A2 (en) | 2002-05-29 |
| KR20020087041A (ko) | 2002-11-21 |
| MXPA02000888A (es) | 2002-07-30 |
| CA2382755A1 (en) | 2001-02-01 |
| RU2002105011A (ru) | 2004-01-20 |
| ATE423113T1 (de) | 2009-03-15 |
| CR6563A (es) | 2008-11-25 |
| AU6462800A (en) | 2001-02-13 |
| SK1182002A3 (en) | 2002-11-06 |
| ZA200200543B (en) | 2003-08-27 |
| IL147495A0 (en) | 2002-08-14 |
| JP4829449B2 (ja) | 2011-12-07 |
| DE60041584D1 (de) | 2009-04-02 |
| NO20020214L (no) | 2002-04-02 |
| BR0013179A (pt) | 2002-04-02 |
| WO2001007436A3 (en) | 2001-08-23 |
| TR200200225T2 (tr) | 2002-06-21 |
| HK1054227A1 (zh) | 2003-11-21 |
| IL147495A (en) | 2007-07-24 |
| HUP0203375A3 (en) | 2005-03-29 |
| HUP0203375A2 (hu) | 2002-12-28 |
| CZ2002323A3 (cs) | 2002-05-15 |
| CN1420882A (zh) | 2003-05-28 |
| JP2003508353A (ja) | 2003-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200045A (et) | Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid | |
| YU47600A (sh) | SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa | |
| DE69830504D1 (de) | Antithrombotische mitteln | |
| ATE272633T1 (de) | Aromatische amiden | |
| DE69831868D1 (en) | Antithrombosemittel | |
| DE69931393D1 (de) | Antithrombotische amide | |
| DE60130771D1 (de) | Substituierte heterocyclische amide | |
| DE69919397D1 (de) | Thrombin-inhibitoren | |
| SE0101675D0 (sv) | Novel composition | |
| BR0013041A (pt) | Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método | |
| MXPA04001323A (es) | Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso. | |
| CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
| BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
| ATE413388T1 (de) | Muskarin antagonisten | |
| MXPA05009611A (es) | Piperidinas sustituidas como nuevos inhibidores de mdm2-p53. | |
| AU2364000A (en) | Heterocyclic amides as inhibitors of factor xa | |
| SE9901077D0 (sv) | Novel use | |
| ATE453389T1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| ATE308540T1 (de) | Antithrombosemittel | |
| DE60041001D1 (de) | Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien | |
| BRPI0411867A (pt) | tiofenilaminoimidazolinas | |
| AU2002339158A1 (en) | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | |
| DE602004011064D1 (en) | Antitrombotische aether |